



Translation

Notice: This document is a translation of the original Japanese document and is for reference purposes only. In the event of any discrepancy between this translated document and the original Japanese document, the latter shall prevail.

August 21, 2026

Alfresa Corporation
WELCIA YAKKYOKU CO., LTD.
Life Log Technology, Inc.

Notice Regarding the Conducting of a Verification Test on Improving Dietary Habits Through PHR-Data-Utilizing Product Proposals and Health Support Services Aimed at Extending Healthy Life Expectancies and Preventing Lifestyle-Related Diseases in Tsukuba City

Alfresa Corporation (head office: Chiyoda-ku, Tokyo; representative director & president: Yusuke Fukujin; hereinafter “Alfresa”), a subsidiary of Alfresa Holdings Corporation, WELCIA YAKKYOKU CO., LTD. (head office: Chiyoda-ku, Tokyo; representative director & president: Junichi Tanaka; hereinafter “Welcia”), and Life Log Technology, Inc. (head office: Chuo-ku, Tokyo; representative director & president: Shigeyuki Tanahashi; hereinafter “Life Log”) have received a contract from Tsukuba City (mayor: Tatsuo Igarashi), Ibaraki Prefecture, to conduct a verification test on methods for improving dietary habits through product proposals and health support services, with the verification test primarily using dietary record data included in personal health records (PHR).*

* PHR: Records of personal health, medical, lifestyle, and other information (verification test primarily uses dietary record data)

1. Background and Purpose

Tsukuba City has announced its Tsukuba Super Science City Scheme, which entails providing new science-based options to contribute to realizing diverse forms of well-being for the city’s residents, with the aim of creating an inclusive community where no one is left behind and thereby addressing the issues faced by people living in Tsukuba City and improving their quality of life. In the medicine and healthcare fields, the city is adopting cutting-edge services for extending healthy life expectancies and preventing lifestyle-related diseases to achieve its ideal community.

The verification test will be advanced as part of the Tsukuba Super Science City Scheme and will involve the provision of product proposals and health support services to members of a test group of the city's residents based on their individual dietary habits, which will be determined based on dietary data collected using a health management app. As daily dietary habits have a massive impact on health, the test looks to determine whether individualized support based on PHR data can influence changes in product selection, purchasing, or dietary habits.

2. Outline of the Verification Test


(1) Name

Tsukuba City Personal Food Recommendation Service Verification Test

(2) Overall Scheme

Test group members will use Life Log's Calomeal health management app to log their dietary data. This data will be utilized to analyze the dietary and nutritional trends of participants to identify trends, such as low levels of protein or high salt intake. Product proposals will then be issued based on these trends. Sales of these products will be offered at 20 stores operated by Welcia within Tsukuba City, while three of these stores will provide nutrition concierge services from registered dietitians.

The test will seek to determine whether these initiatives contribute to dietary improvements by influencing changes in product selection, purchasing, or dietary habits.



(3) Roles of Participant Companies

i. Alfresa

Alfresa will design and manage the overall scheme used in the verification test while implementing the test and compiling the results through coordination with the Tsukuba City government.

ii. Welcia

Welcia's stores and customer contact points will be utilized to offer sales of recommended products and provide nutrition concierge services via which registered dietitians give suggestions on how to address dietary and health issues.

iii. Life Log

Data collected using Life Log's Calomeal health management app will be analyzed for use by AI-powered recommendation functions.

(4) Characteristics of Calomeal

Calomeal is a diet, exercise, and weight management app developed and operated by Life Log. Daily meals can be logged via a single photograph, and AI will analyze these photographs to automatically calculate and log values for a total of 28 different nutritional elements, including those for calories, protein, lipids, carbohydrates, salt, sugar, fiber, vitamins, and minerals. This feature allows the app to support health management in terms of both weight loss and nutritional balance. Furthermore, Calomeal also features exercise and vital sign data management functions to facilitate comprehensive health management. As of July 2026, this app had more than 7 million registered users.

3. Verification Test Period and Details

The verification test will be conducted from September 1, 2026 to January 31, 2027. During this period, test group members will be recruited, data will be collected through the Calomeal health management app, product proposals and health support services will be provided, and their benefits will be verified. The results of the test will be compiled after completion.

4. Outlook

The insight gained through the verification test will be utilized to support presymptomatic and preventive medicine efforts and to develop business models and commercialization frameworks for promoting the social adoption of the scheme used in said test.

Contact Information

Corporate Communication Department, Alfresa Holdings Corporation

Email: ir@alfresa.com

Secretary and Public Relations Department, WELCIA YAKKYOKU CO., LTD.

E-mail: cc@welcia.co.jp

Public Relations Team, Life Log Technology, Inc.

E-mail: pr@calomeal.com

About the Alfresa Group

The Alfresa Group is a leader in the Japanese healthcare industry and is dedicated to making its corporate philosophy, “we create and deliver a fresh life for all,” come true through a wide range of business lines, including ethical pharmaceuticals wholesaling, OTC pharmaceuticals wholesaling, pharmaceutical manufacturing, operating dispensing pharmacies, regenerative medicine-related business, and CRO business. Alfresa Holdings Corporation (TSE:2784) reported consolidated revenue of ¥3.1 trillion for the fiscal year ended March 31, 2026. For more information, please see: <https://www.alfresa.com/eng/>